Multiple Sclerosis At the Limits 2024 + Include: 12 videos + 12 audios + 12 file sub vtts + 1 pdf, size: 5.48 GB + Target Audience: multiple sclerosis specialists, neurologists, immunologists, neurophysiologists + Information: The 8th Annual Multiple Sclerosis at the Limits (MSATL) conference is a two-day medical education meeting which brings together a notable faculty of globally acknowledged MS experts who will consider new discoveries and therapies at the limits of MS treatments. Audience Multiple Sclerosis Specialists, Neurologists, Rehabilitation Specialists, Immunologists, Neurophysiologists, Scientists, Researchers. Multiple Sclerosis at the Limits is supported by way of grants and sponsorship from the pharmaceutical industry. Supporters have no involvement in the organisation of the event or the selection of speakers or topics, which are selected independently by the event Chairs. Supporters are invited to send a delegation of senior company representatives to attend, and their role is simply to continue building the crucial understanding between academia and industry in a scientific setting. Full disclosure of contacted supporters will appear on the event website and be available at the venue during the event. + Topics: Thursday, 24 October 2024 10:30 am – 11:00 am Badge Collection & Coffee 11:00 am – 11:40 am Anti-CD40L antibodies in relapsing multiple sclerosis Professor Patrick Vermersch 11:40 am – 12:20 pm Capturing disease activity and progression by blood biomarkers in clinical practice – are we there yet? Professor Jens Kuhle 12:20 pm – 1:00 pm Imaging in MS – new approaches to counter microglia-driven neurodegeneration in MS. Professor Laura Airas 1:00 pm – 1:50 pm Lunch 1:50 pm – 2:30 pm The eClinicalMedicine Annual Lecture – introduced by Elena Bellafante, editor, eClinicalMedicine Novel treatments in MS in 2024 including RIPK1 inhibition Professor Heinz Wiendl 2:30 pm – 3:45 pm Industry Satellite Symposium: Roche 3:45 pm – 4:10 pm Break 4:10 pm – 4:50 pm The Lancet Neurology Annual Lecture – introduced by Dr Heather Brown, Senior Editor, The Lancet Neurology Women in MS – the 2024 situation Professor Kerstin Hellwig 4:50 pm – 5:30 pm Low-field strength portable MRI scanners – lowering financial and technical barriers to neuroimaging Professor Derek Jones 5:30 pm – 6:10 pm Deep phenotyping for precision medicine in MS Dr Amit Bar-Or 6:10 pm Close & Networking Reception (1 hr) Friday, 25 October 2024 8:00 am – 8:30 am Welcome Coffee 8:30 am – 9:10 am Early intervention to slow MS progression Dr Jiwon Oh 9:10 am – 9:50 am Clinical & paraclinical outcome measures in clinical trials evaluating progressive disease biology (or repair) Professor Maria-Pia Sormani 9:50 am – 10:15 am Break 10:15 am – 10:55 am The MS prodrome and RIS Professor Christine Lebrun-Frenay 10:55 am – 12:10 pm Industry Satellite Symposium: Novartis 12:10 pm – 1:00 pm Lunch 1:00 pm – 1:40 pm Genetic differences affecting disease course and severity in MS Dr Adil Harroud 1:40 pm – 2:55 pm Industry Satellite Symposium: Neuraxpharm 2:55 pm – 3:05 pm Comfort Break 3:05 pm – 3:45 pm Antidrug-Antibodies in MS Professor Angray Kang 3:45 pm Close
